Case Reports in Medicine

Case Reports in Medicine / 2012 / Article

Case Report | Open Access

Volume 2012 |Article ID 168785 |

Allen N. Stawis, Diane Maennle, Moreno Festuccia, Zia Uddin, Benedetto Bruno, "Recurrent Plasmacytomas after Allografting in a Patient with Multiple Myeloma", Case Reports in Medicine, vol. 2012, Article ID 168785, 5 pages, 2012.

Recurrent Plasmacytomas after Allografting in a Patient with Multiple Myeloma

Academic Editor: Graham F. Pineo
Received06 Sep 2012
Revised25 Nov 2012
Accepted12 Dec 2012
Published25 Dec 2012


Extramedullary recurrence in multiple myeloma patients has been reported after both autologous and allogeneic hematopoietic cell transplantation and, more recently, after treatment with so-called new drugs with potent antimyeloma activity. Only a very few sizable reports focused on its clinical presentation and its incidence, which may be highly underestimated, and most observations are based on single patients reported from several institutions. Given the unusual sites of recurrence, diagnosis may be rather difficult and delayed treatment may play a relevant role in prognosis. Here we report a case of a myeloma patient, initially treated with an allograft, who enjoyed an eleven-year disease-free remission with very good quality of life. She eventually relapsed first with an extramedullary plasmacytoma in the breast and, two years later, with a right atrial cardiac mass.

1. Introduction

Allografting is considered a potentially curative treatment for multiple myeloma, although long-term disease control remains an issue [1]. The frequency of posttransplant extramedullary recurrence and of extramedullary plasmacytoma (EMP) without marrow plasma cell infiltration is reported variably among institutions even after both autologous and allogeneic transplantation [211]. Similarly, the selection of diagnostic laboratory tests and imaging techniques vary among physicians, although early detection of recurrence may have a significant impact on treatment outcome. Here we report a case of EMP in the breast and in the atrium occurring 11 and 13 years after an allograft, respectively. We also illustrate the potential usefulness of serum free light chains (FLC) and their ratio in the diagnosis and followup of EMP.

2. Case Presentation

In June 1998, a 45-year-old lady complained to her family physician about fatigue, pain in the lower extremities, and inability to concentrate at her job. The physical examination revealed the patient to be pale with a hemoglobin of 4.9 g/dL. She was then referred to a hematologist-oncologist. Immunofixation (IFE) studies of serum and urine were positive for monoclonal serum proteins (M-proteins). Bone marrow biopsy submitted in formalin revealed 100% involvement by monoclonal plasma cells. No cytogenetic or FISH studies were routinely performed at that time. A metastatic bone survey showed no osseous abnormality. She was staged as Durie-Salmon Stage II, International Staging System II. Induction therapy consisted of 2 cycles of standard VAD (vincristine, adriamycin, and dexamethasone) regimen. After the first cycle, the serum and urine remained positive for M-proteins. A second cycle was given and there was no adequate response. Given the unsatisfactory response and the young patient age, she underwent an allograft from her sister in December 1998, after a conditioning with total marrow irradiation, busulfan and cyclophosphamide. The posttransplant course was rather uneventful except for a hepatitis B reactivation syndrome (after immunosuppressant therapy) successfully treated with lamivudine. Two years after the allograft, the bone marrow evaluation showed complete remission with less than 1% polyclonal plasma cells. Monoclonal proteins were not detected in serum or urine by IFE, and the 24 hour urine total protein was too low for quantification (Table 1).


June 1998 Diagnosis4.99.1100.73.9Monoclonal λMonoclonal λUrine protein = 17.9 g/24 hrs, 85% free λchains
December 1998 
Allogeneic Stem Cell Transplantation

December 199911.89.4110.62.1Normal Normal Urine protein = 0.2 g/24 hrs

December 200014.09.6130.71.3Normal Normal Urine protein too low for quantification

December 2001 
Mammogram: No evidence of malignancy
14.010140.61.3Normal Normal Urine protein too low for quantification

June 2009 
Right breast plasmacytoma (λ): surgery plus radiation
14.010.3170.61.6Normal Normal Urine protein too low for quantification

July 2011 
Right atrium plasmacytoma (λ)
14.19.8140.6Normal Normal 17 mg/dL urinary protein (random)

October 201213.89.9160.7n.d.n.d.n.d.Urine protein too low for quantification

aSerum reference values (abbreviations): hemoglobin (Hb) = 12–15 g/dL, calcium (CA) = 8.2–10.2 mg/dL, urea (BUN) = 7–22 mg/dL, creatinine (Cr) = 0.2–1.3 mg/dL, beta-2 microglobulin (BMG) = 0.7–3.4 mg/dL, burine reference values: 24 hours rotein = less than 0.15 g/24 hrs, random protein = not established, cIF-Serum: serum immunofixation, dIF-urine: urine immunofixation; n.d.: not done.

The patient continued to do well and pursued a full-time job during the eleven year interval after the allograft. She remained free of myeloma (normal bone marrow, no evidence of discrete lytic or blastic lesions, negative for monoclonal proteins in serum and urine from IFE studies, and urine total protein too low for quantification) until she complained about a right breast mass located towards the axilla during a follow-up exam in 2009. Her latest mammogram in 2001 had been negative. The 2.1 cm mass consisted of sheets of monoclonal plasma cells and was diagnosed as solitary plasmacytoma. The EMP was excised and radiation therapy was delivered for five weeks to the right breast tumor bed at a total dose of 5040 cGY. At this time, the bone marrow examination revealed no increase in plasma cells (<1%), and the CT scan indicated no evidence of metastatic disease to the chest, abdomen, pelvis, or lytic or blastic lesions within the skeleton. Serum and urine were negative for M-proteins (IFE studies), and the protein in urine was too low for quantification. For the following two years the patient remained free of any obvious clinical problem and was able to work full-time. Bone marrow examinations in 1999, 2000, and 2009 did not show myeloma recurrence.

Thirteen years after the allograft, she complained of shortness of breath and dyspnea on exertion. She denied any chest pain and any palpitations. The patient was put on albuterol, but continued to have shortness of breath. An echocardiogram in her family physician’s office indicated the presence of a “large right atrial thrombus”, and she was immediately referred to the hospital emergency department. A venous ultrasound of the right and left lower extremities showed no evidence of venous thrombosis. Imaging studies ruled out pneumothorax and/or pulmonary embolism. Echocardiogram documented a normal ejection fraction (60–65%); however, a mass measuring 6.7 × 3.3 cm was seen in the right atrium encroaching the right atrial wall and a large pericardial effusion with tamponade. CT confirmed a large right cardiac atrial mass, extending into the inferior vena cava and also involving the superior vena cava as it enters the atrium and the pericardial effusion (Figure 1). The patient then underwent a pericardial window to drain the pericardial effusion. The effusion cytology showed that 50% of the cells were plasma cells, which was confirmed by immunoperoxidase CD138 positive staining. In situ hybridization stains for kappa and lambda chains indicated that almost all of the plasma cells were positive for lambda light chains. The diagnosis of monoclonal plasmacytosis was made. Biopsy of the pericardial tissue ruled out other malignancies, amyloidosis, and vasculitis.

Transcatheter biopsy of the right atrial cardiac mass by fluoroscopic guided road-mapping was performed. The tissue sample consisted of sheets of plasma cells. The diagnosis of EMP was confirmed with a combination of immunoperoxidase staining for CD138, which showed strong positivity, and in situ hybridization for kappa and lambda, which confirmed monoclonality since all of the cells stained for lambda chains (Figures 2(a) and 2(b)). Flow cytometry was negative due to poor cell survival. Bone marrow biopsy showed normocellular marrow with 100% donor chimerism. The B cells were polyclonal by flow cytometry and there was no evidence of monoclonality within the plasma cells. In situ hybridization revealed a normal kappa/lambda ratio of 1.4 : 1. MRI of the spine was unremarkable, without any evidence of canal or neural foraminal stenosis or of myelomatous disease. Chemotherapy with monthly cycles of bortezomib and dexamethasone was initiated and the patient was monitored with serial serum FLC assay, CT and echocardiography. After four months, the tumor exhibited a substantial reduction in size measuring 4.7 cm on echocardiogram and CT scan. Serum free lambda chain concentration decreased linearly, with simultaneous increase in the kappa/lambda ratio (Table 2). The patient is alive and well at this writing, in partial remission by the International Uniform Response Criteria for multiple myeloma, 14 years posttransplant [1214]. She is receiving continuous chemotherapy (bortezomib, dexamethasone, and now Cytoxan) despite an episode of DVT in the right leg (3/2012) and a recent syncopal event (7/2012). The atrial mass measures 4.1 × 0.9 cm in greatest dimensions by transesophageal echocardiography (11/2012).

Free Kappa (mg/dL)
Normal: 0.33–1.94
Free Lambda (mg/dL)
Normal: 0.57–2.63
Free Kappa/Lambda Ratio
Normal: 0.26–1.65
Chemotherapy with bortezomib and dexametasone

August 20110.7827.70.03Start Cycle 1
September 20110.183.30.05Start Cycle 2
October 20110.982.40.41Start Cycle 3
November 20110.871.30.66Start Cycle 4
October 20120.751.2.0.62

3. Discussion

We believe that this case of a lambda chain myeloma patient, who had an allograft, experienced 2 EMP, after a long clinical remission, exhibits rather interesting features: (a) a long disease-free survival without maintenance/consolidation treatment with very good quality of life after the allograft; (b) extramedullary relapse as solitary EMP of the breast 11 years after the allograft; (c) two years later a second EMP of the right cardiac atrium. Bone marrow studies invariably showed no evidence of marrow plasma cell infiltration with 100% donor chimerism, thus indicating the confinement of myeloma relapse only to the soft tissues.

Extra-medullary relapse of myeloma with sparing of the marrow after both autologous and allogeneic transplantations and, more recently, after therapy with novel agents such as thalidomide, lenalidomide, and bortezomib, is a mode of recurrence the frequency of which is undetermined and may be highly underestimated. Only a few reports have evaluated EMP incidence, clinical characteristics, and prognosis, and most of these are summarised in case reports [211]. Moreover, definitions of EMP lesions vary among study groups [15].

Varettoni et al. reported an incidence of extramedullary recurrence of 6% on a series of 1003 myeloma patients, which was found to be associated with shorter overall and progression survivals [9]. Zeiser et al. reported a higher incidence after autologous and allogeneic transplantation [8]. Numerous sites of involvement such as lungs, soft tissues, pericardium, skin and central nervous system were reported. The mechanisms underlying the selective involvement of extramedullary sites remain undefined. It may be postulated that these mechanisms may be due to recurrence in sanctuary sites where myeloma cells are resistant to intense therapy, or to a stronger putative graft-versus-myeloma effect in the marrow as compared with peripheral tissues after an allograft.

A major concern for clinicians is the early detection of the recurrence, because delayed diagnosis may compromise treatment efficacy. Delayed diagnosis is particularly frequent when the clinical presentation of the recurrence is rather unusual, skeletal radiological surveys are negative, and monoclonal paraproteins are undetectable. Even though techniques such as MRI and PET imaging may be of value for monitoring the patient, more readily available and less expensive laboratory assays should be sought. In our patient, serum (SPE) and urine protein electrophoreses (UPE), and IFE (serum and urine) were negative at the time both breast and atrial masses were noted, therefore indicating the lack of sensitivity of these tests for the early diagnosis of solitary EMP. By contrast, only the serum free lambda chains were ten fold higher than the normal value, and the free light chain ratio was abnormal, which suggests its potential usefulness in the early detection of posttransplant extramedullary recurrence.

Although the role of serum FLC assay is still a matter of debate to determine stringent clinical complete remission, it may be particularly relevant for early detection and followup of EMP where more sensitive methods such as flow cytometry and/or FISH analysis cannot be performed on an uninvolved bone marrow [1618]. In addition to the light chain myeloma, 95% of the intact monoclonal immunoglobulin (M-Ig) myelomas have an abnormal serum FLC concentration and ratio. The malignant plasma cells most often screte FLC in addition to intact immunoglobulins. Recently in both nonintensive or more intensive therapy in M-Ig MM, three new developments were reported: (1) relapse as EMP with a marked increase in serum FLC (also designated as light chain escape) in the absence of a parallel rise in M-Ig [19]; (2) clonal change at relapse, identified as patients who produced a M-Ig at presentation but relapsed with rising production of serum FLC and stable or falling M-Ig concentration in the serum [20, 21]; (3) early detection of relapse of M-IgA MM after autologous SCT by newly developed Hevylite assay [22], which utilizes antibodies specific for the intersection of the heavy chain and light chain of each immunoglobulin, and allows separate quantification of each immunoglobulin heavy and light chain combination [23]. Overall, reports suggested that FLC were more sensitive for the early detection of EMP as compared to other laboratory tests. We now incorporate the following protocol in the clinical pathway for monitoring myeloma patients in clinical remission after transplant: (i) serum FLC assay prior to the start of treatment; (ii) serum FLC assays every two weeks for three months to evaluate response to treatment; (iii) serum FLC assays every three months unless the patient develops overt myeloma symptoms. A prospective study on a large cohort of myeloma patients is in progress.

EMP and extramedullary recurrence are rather challenging to treat. A “standard” therapeutic approach is not currently available. At present, most treatments are individualized and include a wide range of strategies such as radiation therapy, new drugs, and donor lymphocyte infusions after an allograft [211]. In our patient, the first EMP in the breast was treated with surgical excision and radiotherapy that allowed for a remission duration of 2 years until a new mass in the right cardiac atrium led to the diagnosis of a second EMP which responded to bortezomib and dexametasone.

Current large prospective clinical trails should include side studies that longitudinally evaluate incidence, clinical presentation, and prognosis of extramedullary recurrence. Moreover, retrospective analyses on large series of patients from study groups such as the European Myeloma Network and/or Bone Marrow Transplantation Registries may be helpful to better define this clinical entity. Finally, simple and sensitive diagnostic tests are needed for timely diagnosis that may allow for improved treatment outcomes.

Conflict of Interests

No conflict of interests is declared (employment or leadership, consultant or advisory role, stock ownership, or honoraria).


  1. B. Bruno, L. Giaccone, R. Sorasio, and M. Boccadoro, “Role of allogeneic stem cell transplantation in multiple myeloma,” Seminars in Hematology, vol. 46, no. 2, pp. 158–165, 2009. View at: Publisher Site | Google Scholar
  2. B. Wirk, J. R. Wingard, and J. S. Moreb, “Extramedullary disease in plasma cell myeloma: the iceberg phenomenon,” Bone Marrow Transplant. In press. View at: Google Scholar
  3. S. Madan and S. Kumar, “Review: extramedullary disease in multiple myeloma,” Clinical Advances in Hematology and Oncology, vol. 7, pp. 802–804, 2009. View at: Google Scholar
  4. J. A. Pérez-Simón, A. Sureda, F. Fernández-Aviles et al., “Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients,” Leukemia, vol. 20, pp. 542–545, 2006. View at: Google Scholar
  5. E. Terpos, K. Rezvani, S. Basu et al., “Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma,” European Journal of Haematology, vol. 75, no. 5, pp. 376–383, 2005. View at: Publisher Site | Google Scholar
  6. J. L. Byrne, J. Fairbairn, B. Davy, I. G. Carter, E. M. Bessell, and N. H. Russell, “Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission,” Bone Marrow Transplantation, vol. 31, no. 3, pp. 157–161, 2003. View at: Publisher Site | Google Scholar
  7. A. Alegre, A. Granda, C. Martínez-Chamorro et al., “Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry,” Haematologica, vol. 87, no. 6, pp. 609–614, 2002. View at: Google Scholar
  8. R. Zeiser, B. Deschler, H. Bertz, J. Finke, and M. Engelhardt, “Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome,” Bone Marrow Transplantation, vol. 34, no. 12, pp. 1057–1065, 2004. View at: Publisher Site | Google Scholar
  9. M. Varettoni, A. Corso, G. Pica, S. Mangiacavalli, C. Pascutto, and M. Lazzarino, “Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients,” Annals of Oncology, vol. 21, no. 2, pp. 325–330, 2010. View at: Publisher Site | Google Scholar
  10. F. Patriarca, S. Prosdocimo, V. Tomadini, A. Vasciaveo, B. Bruno, and R. Fanin, “Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloabiatlve allogeneic transplantation,” Haematologica, vol. 90, no. 2, pp. 278–279, 2005. View at: Google Scholar
  11. A. Paulus, A. Swaika, K. C. Miller et al., “Clinical relapse in a patient with multiple myeloma presenting as an atrial plasmacytoma,” Journal of Clinical Oncology, vol. 29, no. 3, pp. e47–e49, 2011. View at: Publisher Site | Google Scholar
  12. B. G. Durie, J. L. Harousseau, J. S. Miguel et al., “International uniform response criteria for multiple myeloma,” Leukemia, vol. 20, pp. 1467–1473, 2006. View at: Google Scholar
  13. B. G. Durie, J. L. Harousseau, J. S. Miguel et al., “Erratum: international uniform response criteria for multiple myeloma,” Leukemia, vol. 20, article 1134, 2006. View at: Google Scholar
  14. B. G. Durie, J. L. Harousseau, J. S. Miguel et al., “International uniform response criteria for multiple myeloma,” Leukemia, vol. 21, article 1134, 2007. View at: Google Scholar
  15. L. Billecke, E. M. Penas, A. M. May et al., “Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma,” Anticancer Research, vol. 32, pp. 2031–2034, 2012. View at: Google Scholar
  16. A. Dispenzieri, R. Kyle, G. Merlini et al., “International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders,” Leukemia, vol. 23, no. 2, pp. 215–224, 2009. View at: Publisher Site | Google Scholar
  17. N. Kröger, S. Asenova, A. Gerritzen, U. Bacher, and A. Zander, “Questionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients,” Blood, vol. 115, no. 16, pp. 3413–3414, 2010. View at: Publisher Site | Google Scholar
  18. G. Pratt, G. P. Mead, K. R. Godfrey et al., “The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains,” Leukemia and Lymphoma, vol. 47, no. 1, pp. 21–28, 2006. View at: Publisher Site | Google Scholar
  19. M. A. Dawson, S. Patil, and A. Spencer, “Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains,” Haematologica, vol. 92, no. 1, pp. 143–144, 2007. View at: Publisher Site | Google Scholar
  20. J. A. R. Hobbs, M. T. Drayson, K. Sharp, S. Harding, A. R. Bradwell, and G. P. Mead, “Frequency of altered monoclonal protein production at relapse of multiple myeloma,” British Journal of Haematology, vol. 148, no. 4, pp. 659–669, 2010. View at: Google Scholar
  21. A. Kühnemund, P. Liebisch, K. Bauchmüller et al., “'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring,” Journal of Cancer Research and Clinical Oncology, vol. 135, no. 3, pp. 477–484, 2009. View at: Publisher Site | Google Scholar
  22. L. J. Donato, S. R. Zeldenrust, D. L. Murrat, and J. A. Katzmann, “A 71-year old woman with multiple myeloma status after stem cell transplantation,” Clinical Chemistry, vol. 57, pp. 1645–1649, 2011. View at: Google Scholar
  23. A. R. Bradwell, Serum Free Light Chain Analysis (Plus Hevylite), The Binding Site Group, Birmingham, UK, 6th edition, 2010.

Copyright © 2012 Allen N. Stawis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.